Stock ALGS ALIGOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Aligos Therapeutics, Inc.

Equities

ALGS

US01626L1052

Real-time Estimate Cboe BZX
Other stock markets
 17:28:57 22/05/2024 BST 		5-day change 1st Jan Change
0.663 USD +3.84% Intraday chart for Aligos Therapeutics, Inc. -2.81% -0.60%
04-03 Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects CI
03-27 Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
GL
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
GL
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
GL
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
AQ
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
AQ
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
GL
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
GL
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
AQ
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
GL
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
GL
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
AQ
Aligos Therapeutics, Inc. Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
CI
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
GL
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
CI
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
GL
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
AQ
Aligos Therapeutics, Inc. Announces the Initiation of the Phase 2a HERald Study of ALG-055009 in MASH Subjects
CI
Aligos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
GL
Aligos Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALGS Stock
  4. News Aligos Therapeutics, Inc.